COMPANY OVERVIEW
Who we are
Welcome to NURAVAX: Leading the Way in Neurodegenerative Immunotherapy
NURAVAX stands at the cutting edge of biopharmaceutical innovation, specializing in groundbreaking immunotherapy treatments for neurodegenerative disorders. We recognize the global challenge posed by Alzheimer’s disease - a condition impacting millions worldwide, not just the patients but also their caregivers and families.

Our pioneering technology represents a leap forward in this field. It effectively navigates previously insurmountable hurdles and has shown exceptionally promising results, particularly in treating the elderly - a group often hardest hit by these conditions.
NURAVAX's vaccine platform is built on over 18 years of extensive research, developed in collaboration with the Institute for Molecular Medicine, various universities, and the NIH. This foundation of shared expertise and innovation underpins our technology's effectiveness
Alzheimer's disease (AD) is a major focus at NURAVAX for compelling reasons:
Widespread Impact: In the United States, Alzheimer’s affects an estimated 7 million people, with prevalence rising sharply in older age groups – 19% among those aged 75-84 and 42% in individuals over 84.
Lack of Effective Treatments: To date, there is a lack of preventive and therapeutic medications that have shown significant efficacy in combating Alzheimer's, underscoring a dire need for innovative solutions.
Complex Pathology: Despite extensive research, the exact causes of AD remain elusive. However, studies consistently indicate that beta-amyloid and tau proteins play a detrimental role in its progression.
Early Onset, Late Detection: AD begins to develop in people as young as 40-50 years old, often without noticeable symptoms, making early detection challenging.
Immunotherapy: An Effective Frontier in Alzheimer’s and Parkinson’s Treatment
At NURAVAX, we believe in the power of immunotherapy as a groundbreaking approach to treat Alzheimer’s and Parkinson’s diseases. Our focus is on developing vaccines to stimulate the body's own immune response against key pathological factors: beta-amyloid, tau proteins, and a-synuclein.
Targeted Antibody Response: Our vaccines are designed to induce antibodies that actively target and reduce the harmful effects of Abeta, tau, and a-syn.
Preventing Pathological Progression: By forming antigen-antibody complexes within the brain, our approach helps prevent the aggregation and further spread of these pathological molecules. This stops them from binding together to form harmful structures like oligomers, plaques, and tangles.
Eliminating Pathological Agents: Once these harmful molecules are bound by antibodies, they are transferred from the brain into the peripheral circulation. Here, they are effectively identified and eliminated by the body’s immune system.